In this article, we will be taking a look at the 15 best biotech stocks to buy according to billionaires. Although biotech ...

Polish drugmaker Celon Pharma (WSE: CLN) has announced positive results from a Phase II trial of CPL’36, an experimental oral ...

Researchers at Washington University School of Medicine in St. Louis have uncovered why some patients with a rare genetic ...

GOTHENBURG, SE / ACCESS Newswire / March 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, March 12, 2025 - ...

Tardive dyskinesia (TD) is an involuntary movement condition, meaning you can't control your movements. "Tardive" means late, and "dyskinesia" means uncontrolled movements. It's often a side ...

Let’s discuss how Tardive Dyskinesia (TD) affects your life and what you can do to overcome these difficulties.

USA: A recent study has shed light on the progression of otologic and nasal symptoms in children with primary ciliary ...

Tardive dyskinesia places high physical, social, and psychological burdens on patients and their caregivers. A new online survey of U.S. caregivers spotlights their struggles. Share on Facebook.

Celon Pharma’s PDE10A inhibitor has reduced involuntary movements in a phase 2 trial of individuals with Parkinson’s disease.

GOTHENBURG, SE / ACCESS Newswire / March 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, March 12, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and ...

The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.

Normal lung tissue is shown on the left. On the right is lung tissue from a person with primary ciliary dyskinesia with a ...